Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Mary Bird Perkins Cancer Center - Baton Rouge
mi
from
Baton Rouge, LA
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Mary Bird Perkins Cancer Center - Baton Rouge
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
MBCCOP - LSU Health Sciences Center
mi
from
New Orleans, LA
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
MBCCOP - LSU Health Sciences Center
mi
from
New Orleans, LA
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Medical Center of Louisiana - New Orleans
mi
from
New Orleans, LA
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Medical Center of Louisiana - New Orleans
mi
from
New Orleans, LA
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Battle Creek Health System Cancer Care Center
mi
from
Battle Creek, MI
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Battle Creek Health System Cancer Care Center
mi
from
Battle Creek, MI
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Mecosta County General Hospital
mi
from
Big Rapids, MI
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Mecosta County General Hospital
mi
from
Big Rapids, MI
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
CCOP - Grand Rapids
mi
from
Grand Rapids, MI
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
CCOP - Grand Rapids
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Lacks Cancer Center at Saint Mary's Mercy Medical Center
mi
from
Grand Rapids, MI
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Lacks Cancer Center at Saint Mary's Mercy Medical Center
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Spectrum Health Cancer Care-Butterworth Campus
mi
from
Grand Rapids, MI
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Spectrum Health Cancer Care-Butterworth Campus
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Metropolitan Hospital
mi
from
Grand Rapids, MI
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Metropolitan Hospital
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Spectrum Health Hospital - Blodgett Campus
mi
from
Grand Rapids, MI
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Spectrum Health Hospital - Blodgett Campus
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Holland Community Hospital
mi
from
Holland, MI
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Holland Community Hospital
mi
from
Holland, MI
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Hackley Hospital
mi
from
Muskegon, MI
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Hackley Hospital
mi
from
Muskegon, MI
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Northern Michigan Hospital
mi
from
Petoskey, MI
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Northern Michigan Hospital
mi
from
Petoskey, MI
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Munson Medical Center
mi
from
Traverse City, MI
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Munson Medical Center
mi
from
Traverse City, MI
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
CCOP - Montana Cancer Consortium
mi
from
Billings, MT
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
CCOP - Montana Cancer Consortium
mi
from
Billings, MT
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Deaconess Billings Clinic - Downtown
mi
from
Billings, MT
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Deaconess Billings Clinic - Downtown
mi
from
Billings, MT
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Northern Rockies Radiation Oncology Center
mi
from
Billings, MT
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Northern Rockies Radiation Oncology Center
mi
from
Billings, MT
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
St. Vincent Healthcare
mi
from
Billings, MT
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
St. Vincent Healthcare
mi
from
Billings, MT
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Deaconess Billings Clinic Cancer Center
mi
from
Billings, MT
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Deaconess Billings Clinic Cancer Center
mi
from
Billings, MT
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Bozeman Deaconess Hospital
mi
from
Bozeman, MT
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Bozeman Deaconess Hospital
mi
from
Bozeman, MT
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
St. James Community Hospital
mi
from
Butte, MT
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
St. James Community Hospital
mi
from
Butte, MT
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
St. Peter's Hospital
mi
from
Helena, MT
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
St. Peter's Hospital
mi
from
Helena, MT
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Kalispell Regional Medical Center
mi
from
Kalispell, MT
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Kalispell Regional Medical Center
mi
from
Kalispell, MT
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Eastern Montana Cancer Center
mi
from
Miles City, MT
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Eastern Montana Cancer Center
mi
from
Miles City, MT
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Community Medical Center
mi
from
Missoula, MT
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Community Medical Center
mi
from
Missoula, MT
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Montana Cancer Center
mi
from
Missoula, MT
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Montana Cancer Center
mi
from
Missoula, MT
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Methodist Cancer Center at Methodist Hospital - Omaha
mi
from
Omaha, NE
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Methodist Cancer Center at Methodist Hospital - Omaha
mi
from
Omaha, NE
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Blumenthal Cancer Center at Carolinas Medical Center
mi
from
Charlotte, NC
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Blumenthal Cancer Center at Carolinas Medical Center
mi
from
Charlotte, NC
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Wayne Memorial Hospital, Incorporated
mi
from
Goldsboro, NC
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Wayne Memorial Hospital, Incorporated
mi
from
Goldsboro, NC
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Wilson Medical Center
mi
from
Wilson, NC
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Wilson Medical Center
mi
from
Wilson, NC
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Cleveland Clinic Taussig Cancer Center
mi
from
Cleveland, OH
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Cleveland Clinic Taussig Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Grandview Hospital
mi
from
Dayton, OH
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Grandview Hospital
mi
from
Dayton, OH
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Good Samaritan Hospital
mi
from
Dayton, OH
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Good Samaritan Hospital
mi
from
Dayton, OH
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
David L. Rike Cancer Center at Miami Valley Hospital
mi
from
Dayton, OH
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
David L. Rike Cancer Center at Miami Valley Hospital
mi
from
Dayton, OH
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Samaritan North Cancer Care Center
mi
from
Dayton, OH
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Samaritan North Cancer Care Center
mi
from
Dayton, OH
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Veterans Affairs Medical Center - Dayton
mi
from
Dayton, OH
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Veterans Affairs Medical Center - Dayton
mi
from
Dayton, OH
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
CCOP - Dayton
mi
from
Dayton, OH
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
CCOP - Dayton
mi
from
Dayton, OH
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Community Oncology Group - Independence
mi
from
Independence, OH
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Community Oncology Group - Independence
mi
from
Independence, OH
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Charles F. Kettering Memorial Hospital
mi
from
Kettering, OH
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Charles F. Kettering Memorial Hospital
mi
from
Kettering, OH
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Middletown Regional Hospital
mi
from
Middletown, OH
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Middletown Regional Hospital
mi
from
Middletown, OH
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
UVMC Cancer Care Center at Upper Valley Medical Center
mi
from
Troy, OH
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
UVMC Cancer Care Center at Upper Valley Medical Center
mi
from
Troy, OH
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Cleveland Clinic - Wooster
mi
from
Wooster, OH
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Cleveland Clinic - Wooster
mi
from
Wooster, OH
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Ruth G. McMillan Cancer Center at Greene Memorial Hospital
mi
from
Xenia, OH
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Ruth G. McMillan Cancer Center at Greene Memorial Hospital
mi
from
Xenia, OH
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Providence Milwaukie Hospital
mi
from
Milwaukie, OR
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Providence Milwaukie Hospital
mi
from
Milwaukie, OR
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Comprehensive Cancer Center at Legacy Good Samaritan Hospital & Medical Center
mi
from
Portland, OR
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Comprehensive Cancer Center at Legacy Good Samaritan Hospital & Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Providence Cancer Center at Providence Portland Medical Center
mi
from
Portland, OR
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Providence Cancer Center at Providence Portland Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
CCOP - Columbia River Oncology Program
mi
from
Portland, OR
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
CCOP - Columbia River Oncology Program
mi
from
Portland, OR
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Providence St. Vincent Medical Center
mi
from
Portland, OR
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Providence St. Vincent Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated:  10/3/2017
Institute of Oncology at Vilnius University
mi
from
Portland, OR
S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Status: Enrolling
Updated: 10/3/2017
Institute of Oncology at Vilnius University
mi
from
Portland, OR
Click here to add this to my saved trials